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HS-27a human bone stromal cells, in 2D or 3D coultures, induced cellular plasticity in human prostate cancer ARCaPE and
ARCaPM cells in an EMT model. Cocultured ARCaPE or ARCaPM cells with HS-27a, developed increased colony forming capacity
and growth advantage, with ARCaPE exhibiting the most significant increases in presence of bone or prostate stroma cells. Prostate
(Pt-N or Pt-C) or bone (HS-27a) stromal cells induced significant resistance to radiation treatment in ARCaPE cells compared
to ARCaPM cells. However pretreatment with anti-E-cadherin antibody (SHEP8-7) or anti-alpha v integrin blocking antibody
(CNT095) significantly decreased stromal cell-induced radiation resistance in both ARCaPE- and ARCaPM-cocultured cells. Taken
together the data suggest thatmesenchymal-like cancer cells reverting to epithelial-like cells in the bonemicroenvironment through
interaction with bone marrow stromal cells and reexpress E-cadherin. These cell adhesion molecules such as E-cadherin and
integrin alpha v in cancer cells induce cell survival signals and mediate resistance to cancer treatments such as radiation.
1. Introduction
Prostate cancer is the most frequent tumor in men, aﬄicting
African American males to a greater degree than Caucasians.
Morbidity and mortality are mainly attributable to metas-
tasis; yet the mechanisms associated with progression are
largely unknown. Localized carcinomas are readily removed
surgically, but once a tumor has established metastases,
current therapies are not curative and prolong survival by
only a few years. Metastasis occurs through a multistep
process, where metastatic cells must intravasate local tissues
and enter into and survive in the blood stream. These
cells then extravasate into the secondary tissue and initiate
and maintain micrometastases at distant sites, with the
end result being the development of a metastatic tumor
[1, 2]. During each step of this process, cancer cells exhibit
transdiﬀerentiation properties that allow both the spatial
and temporal expression of epithelial and mesenchymal
properties in response to microenvironment signals and
its own basic survival needs (e.g., motility and invasion
versus proliferation). Thus, a model of cellular transitions, as
opposed to a continual progression to permanent diﬀeren-
tiation state, is emerging as a significant mechanism during
metastasis. A greater understanding of thesemechanisms will
result in clinical improvements and a better control of the
metastasis process.
Epithelial-mesenhymal transition (EMT) was first de-
scribed during development [3, 4]; however an EMT-like
phenotypic change has been observed in a number of solid
tumors [5–7]. This transition is typically characterized by
a loss in E-cadherin and cytokeratin expression. EMT in
cancer, as in development, is associated with an increase
in cell proliferation [8, 9] and the acquisition of a mes-
enchymal phenotype that includes vimentin, N-cadherin,
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and osteopontin expression. In both normal development
EMT and cancer-associated EMT, the loss of E-cadherin
is critical to the diﬀerentiation and maintenance of the
epithelial phenotype and provides a structural link between
adjacent cellular cytoskeletons, which is important for tissue
architecture. Cells that have undergone EMT (E-cadherin
negative mesenchymal cells) subsequently become more
migratory and invasive and proceed to traverse underlying
basement membranes, with an acquired ability to intravaste
the surrounding local tissue and gain access to vascular
conduits. As such, the loss of E-cadherin is rate limiting for
EMT [10, 11]. Recent reports from this laboratory and others
have described a mesenchymal to epithelial reverting tran-
sition (MErT) to occur, where mesenchymal-like prostate
cancer cell lines reexpress E-cadherin to become epithelial-
like, and reestablish cellular adhesion during colonization
within the liver tumor microenvironment [12, 13]. These
findings are shared in clinical metastases of various cancer
origins including breast, colon, and bladder, where robust
membrane expression of E-cadherin was observed, and the
paired more diﬀerentiated primary tumors were E-cadherin
negative [6, 14]. Thus, a reversion of the mesenchymal
phenotype appears to be important in latter stages of
metastasis.
Numerous studies have shown that the underlying influ-
ence of these cellular transitions is a consequence of tumor-
stromal interactions [15, 16]. Coculture studies have found
that the survival and proliferation of cancer cells are inti-
mately linked to the soluble factors in themicroenvironment,
such as EGF, TGF-β, IGF-l that contribute to survival and the
subsequent formation of macrometastasis [17–20]. However,
these factors are not likely to have a direct eﬀect during
initial metastatic colonization, and thus heterotypic and
homotypic cellular adhesion has been proposed to provide
the necessary survival signals for successful colonization [21,
22]. Current state-of-the-art technology does not provide
the necessary resolution to determine at the single cell
level in patients or experimental in vivo systems, individual
cells that have successfully colonized the secondary site.
However, numerous reports have firmly established that
cancer-stromal interactions in vitro or in three-dimensional
(3D) assays accurately mimic the drug sensitivity/resistance
behavior of those cells found within solid tumors in vivo in a
preclinical or clinical setting [23]. Thus, we employed a novel
coculture assay to determine the cellular plasticity of cancer
cells promoted by the bone stroma and the eﬀect of tumor-
stromal interactions on irradiation therapy in prostate
cancer.
The ARCaP model is the only robust prostate cancer
bone metastatic model which demonstrates epithelial to
mesenchymal transition(EMT). The ARCaP progression
model consists of ARCaPE (epithelial) and ARCaPM (mes-
enchymal), where the ARCaPE cells have a bone metastatic
potential of 12.5% and the ARCaPM cells have a bone
metastatic potential of 100%. The ARCaPE and ARCaPM
cells express the classical markers of EMT [24, 25]. Herein
we present findings that ARCaPM cells undergo MErT when
cocultured within the bone microenvironment in 3D and
2D cultures. Additionally, ARCaPE cells that retained an
epithelial phenotype exhibited a measurable growth advan-
tage and retained ability to form colonies, however only
under coculture conditions with bone stroma. Furthermore,
blocking the ability of ARCaPE or ARCaPM cells from E-
cadherin-mediated cell-cell adhesion or integrin alpha v
beta-associated adhesion significantly aﬀected ARCaP cell
survival within bone stroma and sensitized these cells to
radiation treatment.
2. Methods
2.1. Cell Culture. The human prostate cancer cell lines,
ARCAPE, ARCaPM, the HS-27a bone stromal cells (ATCC,
Manasss, VA) and the Pt-N or Pt-C human prostate stromal
cell. Isolation and characterization of the human prostate
cancer RFP-ARCaP cell lines has been reported [26]. Red
Fluorescent Protein- (RFP-) transfected cells were main-
tained in G418 (350mg/mL) prior to experimentation. All
cell lines were grown in a 5% CO2 incubator at 37◦C in
media consisting of T-medium (Invitrogen, Carlsbad, CA)
supplemented with 5% (v/v) fetal bovine serum and 1%
Penicillin-Streptomycin.
2.2. Cocultures. Initial cocultures were performed as previ-
ously described [12, 13] with modifications. Cocultures con-
sisted of 50 000 cells/cm2 of HS-27a bone marrow stromal
cells and 2000 cells/cm2 prostate cancer cells. Cocultures
were maintained in serum-free T-media and plated on tissue
culture dishes.
2.3. Clonogenic Assay. Cells were plated at low densities
in six-well plates for 24 hours and then were irradiated
with the appropriate radiation dose. Twenty-four hours
later, the media were changed and cells were incubated
until they formed colonies having at least 50 or more cells.
Seventeen days later colonies were rinsed with PBS, stained
with methanol/crystal violet dye, and counted. The colony
formation ability was calculated as a ratio of the number of
colonies formed, divided by the total number of cells plated,
times the plating eﬃciency [(# of colonies formed ÷ total
# cells plated) × plating eﬃciency]. For experiments with
cocultures, cells were initially incubated on a mat of stromal
cells for 24 hours and radiated; 4 hours later clonogenic
assay was performed. For antibody-based experiments using
anti-E-cadherin (15 μg/mL, DECMA or SHEP8-7, Sigma)
and anti-integrin alpha-v (20 μg/mL, CNT095) antibody,
cancer cells were treated with respective antibodies for
24 hours prior to plating them on a mat of stromal
cells.
2.4. Radiation. External beam radiation was delivered on
a 600 Varian linear accelerator (Varian Medical Systems,
Inc.Palo Alto, CA) with a 6MV photon beam. A 40 × 40 cm
field size was utilized and Petri dishes were placed on 1.5 cm
of superflab bolus. Monitor units (MUs) were calculated
to deliver the dose to a depth of dmax at a dose rate of
600MU/min.
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2.5. Statistical Analysis. Representative findings are shown
for all experiments, which were performed in triplicate,
repeated a minimum of three times. Student’s t-test was used
to determine the statistical significance between groups.
3. Results
3.1. ARCaP EMT Model Undergoes a Mesenchymal-to-
Epithelial Reverting Transition (MErT). Recently, the ARCaP
model has been described to closely mimic the patho-
physiology of advanced clinical human prostate cancer bone
metastasis [25]. The ARCaPE cells were derived from single-
cell dilutions of the ARCaP cells. These cells exhibit a
cuboidal-shaped epithelial morphology with high expression
of epithelial markers, such as cytokeratin 18 and E-cadherin.
The lineage-derived ARCaPM cells have a spindle-shaped
mesenchymal morphology and phenotype. ARCaPM cells
have decreased expression of E-cadherin and cytokeratins
18 and 19 but increased expression of N-cadherin and
vimentin. These cells have decreased cell adhesion and
increased metastatic propensity to bone and adrenal glands
[27]. The morphologic and phenotypic changes observed in
the ARCaPM cells closely resemble those of cells undergoing
EMT.
Previously, we have demonstrated a Mesenchymal to
Epithelial reverse Transition (MErT) of metastatic prostate
cancer cell lines within an experimental coculture model
and confirmed in patients with liver metastasis [13, 28].
Our findings have recently been confirmed in prostate
cancer bone metastasis where E-cadherin and β-catenin
were robustly expressed in late stage carcinomas [29].
Therefore we sought to identify the significance of the bone
microenvironment within the experimental ARCaP model.
To assess cellular plasticity of the ARCaP EMT model, we
coultured ARCaP cells with HS-27a cells in 3D RWV (rotary
wall vessel) system for 3 days. ARCaPE cells formed larger
prostate organoids than ARCaPM cells (data not shown).
Upon immunohistochemical examination of organoids, we
observed that both ARCaPE and ARCaPM express E-cadherin
and lack N-cadherin expression (Figure 1(a)). To further
examine the influence of tumor-stroma interactions over a
multiday period we utilized a similar 2D cocultures method.
Utilizing immunoctyochemical analysis, we observed a lack
E-cadherin and robust N-cadherin staining after 1 day
in both ARCAPE and ARCaPM cocultures. However by
day 4, both ARCaPE and ARCaPM cells formed tumor
nest that express E-cadherin and lack N-cadherin staining
(Figure 1(b)). It is worthy to note that ARCaPM tumor nest
appeared to develop at much smaller extent, compared to
ARCaPE cocultures.
Since ARCaPE cells formed larger tumor nest and
spheroids when cocultured with HS-27a cells compared to
ARCaPM cells, we sought to further assess if HS-27a cells
preferentially stimulated the growth of ARCaPE cells versus
ARCaPM cells. Utilizing GFP-transfected HS-27a bone mar-
row stromal cells and RFP-transfected ARCaPE or ARCaPM
cells (Figure 2(a)), we examined the proliferative ability
of ARCaP cells in homotypic and coculture conditions.
Growth of RFP-transfected ARCaPE and ARCaPM cells,
respectively, was quantified by relative fluorescent units
(RFU) of transfected cell lines over a 6-day period in
homotypic cultures and coculture conditions (Figure 2(a)).
As previously reported, homotypic cultured ARCaPM shows
significant growth compared to ARCaPE homotypic cultures;
however cocultures reversed this trend with ARCaPE cells
demonstrating the most significant growth (Figure 2(b)). We
also confirmed these findings in ARCaPE cells in coculture
using clonogenic assay. Although ARCaPM cells have a
higher plating eﬃciency than ARCaPE cells, ARCaPE cells
exhibited an 8-fold increase in their ability to form colonies
after coculture compared to 1.35-fold increase of cocultured
ARCaPM cells (Figure 2(c)). Phase-contrast microscopy of
colonies after coculture shows that ARCaPM colonies appear
loosely adherent, while ARCaPE cells are compact and
interact physically with few of the bone stromal fibroblast
(Figure 2(d)). Taken together, these results demonstrate that
ARCaPM cells reexpress E-cadherin when grown with bone
stromal cells for longer periods. Additionally, ARCaPE cells
which have high levels of E-cadherin gain enhanced growth
and self-renewal ability when cocultured with bone stromal
cells.
3.2. Stromal Cells Influence Radiation Treatment in Prostate
Cancer Cells. Mesenchymal cancer cells have been thought to
be more tumorigenic, aggressive, and resistant to treatments
when compared to epithelial cancer cells [30]. A similar
trend was observed in both ARCaPE and ARCaPM cells after
(4Gy) irradiation treatment. ARCaPM homotypic cancer
cells are more resistant to radiation treatment compared
to ARCaPE homotypic cancer cells (Figure 3(a)). However,
ARCaPM cocultures did not aﬀect the radiation sensitivity
of ARCaPM cancer cells. The highly sensitive ARCaPE cells
exhibit a significant increased resistance to radiation therapy,
up to 3-fold, as result of their interaction with bone stromal
cells (Figure 3(a), P < .01).
To further assess the role of the prostate stromal cells
on tumor-stromal interactions influencing ARCaP cellular
behavior, we cocultured paired prostate stromal fibroblasts
isolated either from normal (Pt-N) or from cancer-associated
regions (Pt-C) [31]. Again, ARCaPE cells cocultured with
(Pt-N) or (Pt-C) exhibited a 7-fold and 8-fold increase in
colony formation, respectively (Figure 3(b), P < .01). We
also saw a similar trend in a growth analysis assay (data not
shown). However when measuring clonogenic ability after
radiation treatment, ARCaPE cells cocultured with either
Pt-N or Pt-C had increased radiation resistance, with a 2-
fold diﬀerence observed between homotypic cultured cells.
Although a significant increase in clonogenic formation
was observed in Pt-C versus Pt-N cocultures (P < .05),
this did not significantly eﬀect the radiation sensitivity of
ARCaPM cells (Figures 3(c)). Taken together, both bone
and prostate stromal cell have a grown inductive eﬀect on
ARCaPE cancer cells and mediate radiation resistance (up to
2-3 fold) in epithelial cancer phenotype, but not in ARCaPM
mesenchymal cancer cells.
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Figure 1: 3D cocultures of ARCaPE or ARCaPM with HS-27a cells show E-cadherin expression. (a) 1 × 107 ARCaPE or ARCaPM were
cocultured with HS-27a cells in RWV for 3 days. Immunohistochemistry of organoids was stained with anti-E-cadherin or N-cadherin
antibody. (b) 2D Cocultures of HS-27a were preformed utilizing a total of 50,000 cm2/HS-27a fibroblasts, after which 20,000 cm2 ARCaPE
or ARCaPM were seeded on top of the fibroblast monolayer. The cocultures were maintained in serum-free medium for 1 or 4 days.
Immunocytochemistry of cocultures over these time periods was performed utilizing anti-E-cadherin and N-cadherin antibodies. Shown
are the EMT/MET of ARCaPEcells (top panels) and MErT of ARCaPMcells (bottom panels).
3.3. Blocking Adhesive Contact Eﬀects Radiation Sensitivity of
Cocultured ARCaP Cells. The importance of cell adhesion
(i.e., cell-cell and cell-ECM adhesion) on the survival of
disseminated cancer cells has been well documented as
a requirement for colonization and survival within the
metastatic microenvironment [32–34]. Therefore we utilized
a well-known E-cadherin blocking antibody (SHEP8-7)
and a pan-integrin antibody (CNT095) that targets human
alpha-v-integrin and also was shown to block prostate tumor
growth within bone [35]. Since ARCaPE cells express high
levels of the epithelial marker E-cadherin, and ARCaPM cells
can be microenvironmentally induced to express E-cadherin,
we tested whether either of these blocking antibodies would
aﬀect the colony forming ability of either ARCaPE or
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Figure 2: ARCaPE cells show a growth and colony forming capacity advantage in presence of HS-27a cells. (a) and (b) ARCaPM cells were
cocultured in the presence of GFP-HS-27a cells over a 6-day period. Growth of RFP. ARCaPE or ARCaPM human prostate cancer cells was
assessed by RFUs (relative fluorescent units) in the presence cocultures over a 6-day period. Results are means ± SE of three independent
experiments. ∗P < .05 (students t-test) compared to cell number at day 1 ± SEM. (c) Clonogenic colony forming capacity of ARCaPE and
ARCaPM prostate cancer cell after coculture ± SEM. ARCaPM data were normalized to ARCaPM control, and ARCaPE data were normalized
to ARCaPE control (Note HS-27a induced slightly (1.35x) the growth of ARCaPM cells but markedly (8x) the growth of ARCaPE cells.). (d)
ARCaPE or ARCaPM cells were cocultured with HS-27a cells. Shown are phase contrast images of colonies formed in the clonogenic assay.
ARCaPM bone stroma-cocultured cells. Pretreatment with E-
cadherin antibody did not aﬀect the colony forming capacity
of either ARCaPE or ARCaPM homotypic cultured cells;
however it significantly reduced the ability of ARCaPM-
(P < .001) and ARCaPE- (P < .01) coultured cells to
form colonies (Figure 4). Additionally, E-cadherin block-
ing antibody pretreatments further increased sensitivity to
radiation treatment of ARCaPM cells in homotypic and
cocultured conditions, similarly (P < .01). E-cadherin
blocking antibody-pretreated ARCaPE cells showed the most
significant increased sensitivity to radiation treatment in
homotypic compared cocultured conditions (P < .001),
however a significant reduction in colony formation, to
a lesser extent, was observed in ARCaPE cocultured cells
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Figure 3: Cocultured ARCaPE cells gain cell colony forming capacity and radiation resistance when grown with bone and prostate stromal
cells. (a) ARCaPE or ARCaPM cocultured cells were irradiated 24 hours after coculture with HS-27a cells and cancer cell colony forming
capacity was assayed using clonogenic assay. Results are means ± SE of three independent experiments. ARCaPM experimental data are
normalized to ARCaPM control and ARCaPE experimental data are normalized to ARCaPE control (a). ARCaPE cells cocultured with prostate
stromal fibroblasts Pt-C (Cancer associated fibroblasts) or Pt-N (Normal/benign fibroblasts) were irradiated and compared to nonirradiated
cocultures. Cell colony forming capacity was assayed by clonogenic assay. Data are normalized to ARCaPE control levels. (b) ARCaPM cells
cocultured with Pt-C or Pt-N were irradiated and compared to nonirradiated cocultures (c). Cell colony forming capacity was assayed by
clonogenic assay. Data are normalized to ARCaPM control levels.
(Figure 4, P < .01). Therefore, targeting E-cadherin limited
both epithelial and mesenchymal cells ability to form
colonies after coculture with bone stromal cells.
To determine the influence of intergin alpha v cell adhe-
sion with bone microenvironment, we performed similar
clonogenic formation assay. Pretreatment with CNT095 anti-
body significantly decreased the clonogenic ability of both
ARCaPM and ARCaPE cells in homotyic cultures (Figure 5,
P < .001). Additionally, CNT095 significantly decreased
bone stroma-induced radiation resistance in cancer cells in
both ARCaPM (P < .001) and ARCaPE (P < .001) cancer
cells, with the most significant reduction in cocultured
conditions (P < .001) (Figure 5). Taken together, these
results suggest that bone stroma-induced radiation resistance
is mediated through both E-cadherin and integrin alpha v
beta signaling in epithelial and mesenchymal cells. Thus,
E-cadherin and integrin alpha v beta appear to present novel
targets for metastatic and radiation resistant cells.
4. Discussion
It is well documented in prostate and others cancers that
EMT is associated with initial transformation from encapsu-
lated to invasive carcinomas. The mesenchymal phenotype,
which is required for dissemination, has been suggested to
revert to an epithelial phenotype in distant metastasis [13,
14, 29, 36]. This has been evidenced in the primary tumors
which lack E-cadherin expression and, showing nuclear β-
catenin expression, show strong membrane staining for both
E-cadherin and β-catenin in metastatic liver [13] or bone
microenvironment [28, 29]. We have previously shown, in
commonly utilized prostate cancer cells lines DU-145 and
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Figure 4: Eﬀect of Anti-E-cadherin antibody on tumor-stroma interactions. A. ARCaPM and ARCaPE, cells were pretreated with Anti-E-
cadherin antibody (SHEP8-7), cocultured with HS-27a stromal cells for 24 hours, and radiated with 4Gy. Cell colony forming capacity was
assayed using clonogenic assay. ARCaPM data are normalized to ARCaPM control levels, and ARCaPE data are normalized to ARCaPE control
levels.
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Figure 5: Eﬀect of Anti-alpha v integrin (CNT095) on tumor-stroma interactions. ARCaPM and ARCaPE, cells were pretreated with CNT095
antibody was cocultured with HS-27a stromal cells for 24 hours, and radiated with 4Gy. Cell colony forming capacity was assayed using
clonogenic assay. ARCaPM data are normalized to ARCaPM control levels, and ARCaPE data are normalized to ARCaPE control levels.
PC-3, that reexpression of E-cadherin and reversion of the
mesenchymal phenotype is a rate limiting for metastatic
seeding of primary rat hepatocytes [13]. Since bone metasta-
sis is most prevalent in prostate cancers, we sought to extent
these finding utilizing the ARCaP model, which is the first
prostate cancer EMT model demonstrating histomorpho-
logical features and classical markers in a lineage-derived
series of cells, to determine the functional relationship
of this cellular transition. Whether this is accomplished
through exposure to soluble growth factors or the bone
microenvironment, the end result decreased diﬀerentiation
with increased metastatic potential [25, 27, 37].
Our initial results show that ARCaPM cells maintained in
3D Rotary Wall Vessel (RWV) or 2D cocultures underwent
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MErT when cocultured with HS-27a bone stromal cells,
as shown through expression of E-cadherin and of N-
cadherin expression (Figures 1(a) and 1(b)). Moreover
ARCaPE cells show a significant enhancement in colony
formation (8×) and significant growth pattern comparable
to ARCaPM (1.35×) cocultures (Figures 2(b) and 2(c)). A
recent report has shown through RFP cell tracking that
selected ARCaPE clones after in vivo inoculation into the
bone microenvironment gives rise to both ARCaPE and
ARCaPM populations [37]. These findings coupled with
our observed reversion of ARCaPM cells to ARCAPE like
cells suggest that tumor-stromal-induced cellular plasticity
gives rise to distinct populations of cancer cells within
bone microenvironment, the mesenchymal phenotype and
its kinetic characteristics (motility/invasive), and the epithe-
lial characteristics necessary for secondary tumor develop-
ment. The fact that the ARCaPM cells have an increase
propensity for metastasis compared to ARCaPE cells suggest
that dissemination from the primary tumor mass requires
the mesenchymal phenotype. However a mesenchymal to
epithelial transition is associated with initial metastatic
seeding and subsequent formation of a cohesive tumor
mass within the bone microenvironment. This hypothesis
is supported in a bladder cancer model, where lineage-
derived series of EMT-transformed mesenchymal-like cells
exhibit increased lung metastasis in vivo; however secondary
tumor formation is predominantly enhanced by the pres-
ence of epithelial cells compared to mesenchymal cells
[38].
Since epithelial reversion enhances the growth of tumor
cells in bone microenvironment, and this is observed in
multiple experimental models and clinical metastases, there
is a question of whether this transition is required for
metastatic seeding and therefore an avenue for therapeutic
intervention(s). To gain insight into the importance of
this reversion, we utilized ionizing radiation on ARCaPE
and ARCaPM homotypic and cocultured cells. Our results
show that ARCaPE homotypic cultures when compared
to ARCaPM homotypic cultures are more sensitive to
radiation treatment (Figure 3(a)). However in the presence
of bone or prostate stromal cells, ARCaPE cells gained
increased radiation resistance, with increased proliferative
and colony forming capacity (Figures 2(b) and 2(c)). This
phenomenon was not observed in the ARCaPM cocultures.
To determine the underlining causes of this observation, we
hypothesized that cell-cell interactions through E-cadherin
or cell-ECM interactions through integrins may mediate the
stromal induced proliferative eﬀect and radiation resistance
in ARCaPE cancer cells. Using E-cadherin neutralizing
antibody (SHEP8-7) and pan-anti-integrin alpha v antibody
(CNT095), we were able to significantly block the stromal
induced colony forming ability on ARCaPE cancer cells
(Figures 4 and 5). Additionally, both antibodies significantly
blocked the radiation resistance of ARCaPE in cocultured
conditions (Figures 4 and 5). The E-cadherin neutralizing
antibody also had an eﬀect on homotypic ARCaPM-radiated
cells and ARCaPM cells within cocultures (Figure 4). Thus
it appears that blocking bone stroma-induced reexpres-
sion of E-cadherin in ARCaPM in the presence of bone
stromal cells reduced the colony forming capacity of these
cells (Figure 4). The decreased radiation sensitivity of E-
cadherin expressing cells compared to cells lacking E-
cadherin expression has recently been demonstrated in a
cocultured model of MCF-7 (E-cad positive) and MDA-
MB-231 (E-cad negative) cells with normal and radiation-
induced senescent fibroblast [39], where radiation in MCF-
7 cells showed enhanced resistance to radiation treatment
compared to MDA-MB-231 cells. These findings are consent
with our model of a reepithelization requirement within
tumor microenvironment.
CNT095 antibody was toxic to both ARCaPM and
ARCaPE homotypic and cocultured cells. Additionally
CNT095 increased radiation sensitivity, even to a greater
extent than E-cadherin neutralizing antibody treatment
(Figure 5). These findings are consistent with our results
of CTN095 treatment that causes a significantly reduced
number of tumors generated by C4-2B cells, along with a
concomitant increase of cortical bone in mice (unpublished
data). Although C4-2B cells have not been observed to
undergo EMT, this would suggest that targeting the cell-ECM
in vitro and in vivo could be limiting the cell cohesiveness
necessary for metastatic tumor formation.
Targeting of cell adhesion as a therapeutic approach
has been proposed previously. E-cadherin neutralizing anti-
body (SHEP8-7) has been shown to sensitize multicellular
spheroids to microtubule binding therapies in the taxane
family in HT29 human colorectal adenocarcinoma cells [23].
A more recent observation is that survival of androgen
receptor-expressing diﬀerentiated prostate cells is dependent
on E-cadherin and PI3K, but not on androgen, AR, orMAPK
[40]. Given the predominate role for PI3K in cell survival and
reports that PI3K is rapidly recruited to cell membrane to
stabilize E-cadherin junctions [40] and that PI3K activation
requires integrin alpha v activity [41] suggests that PI3K
is possibly responsible for the increased growth and colony
formation gained within the tumor microenvironment.
Thus in the absence of stimulating growth factors, it is
possible that E-cadherin/PI3K or integrin alpha v/PI3K is
involved in a signaling cascade that is initiated by the
tumor microenvironment, at least during initial metastatic
seeding.
In conclusion, our data demonstrate that the E-cadherin
and integrin alpha nctional adhesive interaction is a possible
adjuvant therapy avenue for patients treated with radiation.
Although an in-depth in vivo exploration of targeting
epithelial-like versus mesenchymal-like cells is necessary
to translate these findings to the clinical situation, our
results indeed raise critical questions as to how we view
prostate cancer metastasis and subsequently target metastatic
tumor cells for therapy. Additionally, we have generated an
in vitro model, that closely mimics the clinical situation,
to delineate in a stepwise manner the dynamic tumor-
host interaction(s) that promote cellular plasticity in the
later stages of metastasis. The identification of further key
molecules driving MErT in this system holds promise for
the development of preventative and therapeutic strategies
to minimize metastatic disease.
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